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Abstract 
 
Purpose: Sepsis and its progression are known to have a major influence on the coagulation system. 
Current coagulation tests are of limited use when assessing coagulation in sepsis patients. This study 
aims to assess the potential for a new functional biomarker of clot microstructure, fractal dimension, 
to identify changes in the mechanical properties of clot microstructure across the sepsis spectrum 
(sepsis, severe sepsis and septic shock). Methods: A total of 100 patients that presented acutely to a 
large teaching hospital were included in this prospective observational study (50 sepsis, 20 severe 
sepsis and 30 septic shock) against a matched control of 44 healthy volunteers. Fractal analysis was 
performed, as well as standard markers of coagulation, and six plasma markers of inflammation. 
Results: Fractal dimension was significantly higher in the sepsis and severe sepsis groups than the 
healthy control (1.78 ± 0.07 and 1.80 ± 0.05 respectively vs 1.74 ± 0.03) (p < 0.001), indicating a 
significant increase in mechanical clot strength and elasticity consistent with a hypercoagulable 
state. Conversely, fractal dimension was significantly lower in septic shock (1.66 ± 0.10, p < 0.001), 
indicating a significant reduction in mechanical clot strength and functionality consistent with a 
hypocoagulable state. This corresponded with a significant increase in the inflammatory response. 
Conclusions: This study confirms that clot microstructure is significantly altered through the various 
stages of sepsis. Of particular importance was the marked change in clot development between 
severe sepsis and septic shock, which has not been previously reported.  
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Introduction 
 
Sepsis and its associated underlying inflammatory response are known to exert complex changes on 
the haemostatic system [1]. Defects in the coagulation system have been implied to contribute to 
the development of organ dysfunction and poor outcomes in sepsis [2], however, clinical trials 
aiming to correct these defects have so far failed to provide effective new treatments [3–5]. New 
insights into haemostasis may help to explain the lack of progress in the treatment of sepsis. 
Although currently used clinical markers (aPTT and PT) are useful for monitoring anticoagulation, 
they do not reflect the global picture of coagulation and are insensitive to clinically significant 
coagulation defects [6–8]. Rheometry can be used to scientifically quantify the developing 
mechanical properties of blood as it clots, and has recently been identified as a means for 
quantifying the quality and arrangement of clot microstructure through its fractal dimension (df) [9]. 
df is measured using whole blood, and has been shown to detect hypercoagulable effects even when 
conventional tests of coagulation do not [10]. Abnormal clot microstructure has recently been 
detected in patients with both stroke and cancer using df [10, 11]. However, df has not been used 
previously to quantify clot microstructure across the sepsis spectrum. This study hypothesises that 
the mechanical properties of clot microstructure are significantly altered by the underlying 
inflammatory response across the sepsis spectrum, and that df is able to detect and identify the 
changes from the earlier hypercoagulable phase and the hypocoagulable phase of septic shock in 
terms of clot quality.   
The primary aim of this study was to quantify the changes in mechanical clot quality and 
strength across the stages of sepsis, by using the new marker of clot microstructure, df. 
Some of the data related to the research in this manuscript was presented and published as 
an abstract in the International Symposium of Intensive Care and Emergency Medicine 2016 prior to 
the completion of this study [12]. 
 
 
 
Methods 
 
Study Design 
 
The present study was a single centre prospective observational study carried out in the Emergency 
Department and Intensive Care Unit of a large teaching hospital. This study had full ethical approval 
from the South West Wales Research Ethics Committee. Informed 2-stage written consent was given 
by patients with capacity to do so. Assent was obtained from personal or legal representation in 
cases where capacity to give informed consent was lacking.  
 
Recruitment of Subjects with Sepsis 
 
Subjects that met sepsis criteria as outlined by the American College of Chest Physicians/Society of 
Critical Care Medicine in 1991 [13] were recruited to this study within 24 hours of hospital 
admission. Patients (age ≥ 18 years) were included from October 2011 to March 2014. Patients on 
warfarin or those who had received any treatment likely to affect coagulation (anticoagulation 
including thromboprophylaxis, component replacement) were excluded. Patients with any pre-
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existing disease likely to affect the coagulation profile e.g. chronic renal failure, chronic liver disease, 
malignancy or thrombotic/clotting disorder were also excluded. Furthermore, patients that were 
deemed insensitive to include i.e. impending death were also excluded from the study. 
 Patients were categorised as sepsis, severe sepsis or septic shock at the time of inclusion to 
the study. Categorisation was blinded, and carried out by an intensive care specialist independent of 
the study using the criteria established in 1991 [13]. Sepsis was defined as two or more of the SIRS 
criteria, with evidence of infection. Severe sepsis was defined as sepsis with at least one acute organ 
dysfunction [14] whereas septic shock was defined as sepsis with refractory hypotension including 
perfusion abnormality (lactate >2 mmol/L) in the absence of cardiogenic shock/bleeding. 
 A group of healthy volunteers matched for age, gender and from a demographically similar 
population group was recruited as a healthy control. 
 
Blood Sampling 
 
Blood was sampled immediately on inclusion to the study. The first 5mls of blood was discarded, 
with the following 6.6mls drawn and immediately placed into the rheometer to determine df. 
Further blood samples were drawn into an EDTA vacutainer (Becton, Dickinson and Company, UK, 
Ref: 367839) and a 3.2% sodium citrate vacutainer (Greiner Bio-One GmbH, Austria, Ref: 454327) to 
determine coagulation and inflammatory markers. 
 
Laboratory Markers 
 
Standard coagulation markers (aPTT, PT and fibrinogen) were determined using a Sysmex CA1500 
automated analyser within 2 hours of collection. Platelet count was determined using a Sysmex XE 
2100 automated haematology analyser within 2 hours of collection. Factor VIII activity was 
determined by an aPTT based one-stage assay using appropriate factor deficient plasma and Actin FS 
aPTT reagent (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). D-dimer 
concentration was determined using TriniLIA Auto-D-dimer® turbidimetric assay.   
Inflammatory markers were determined to quantify the inflammatory response at each 
stage of the sepsis spectrum and were selected based on previous studies examining the 
inflammatory effects of sepsis. Concentration of each of the inflammatory markers was measured in 
platelet poor plasma using enzyme-linked immunosorbent assay (ELISA) kits for PCT, TNF-α, IL-6 and 
sE-Selectin. The standard methodology was followed as supplied by manufacturer. 
 
Rheometrical analysis 
 
Gel point analysis was performed using rheometry, to detect the gel point of the coagulating blood 
and quantify the fractal microstructure of the fibrin clot at this point (df). The methodology carried 
out in this study has been described in several previous publications [9], [15–17]. 
 
Computational Analysis 
 
To assess the relationship between df and fibrin mass at the gel point (incipient clot mass), computer 
modelling was carried out. A numerical technique which has previously been used to generate 
random fractal aggregates was used [18, 19]. The algorithm incorporated in this technique uses the 
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box-counting measure of fractal dimension and allows a visual illustration of the incipient clot 
microstructure to be produced, based on the df measurements, and also allows for the 
corresponding fibrin mass to be calculated. 
 
Mature Clot Imaging – Scanning Electron Microscopy 
 
SEM samples were prepared from 12µL of whole blood using the methodology described previously 
[10]. The resultant dehydrated blood samples were coated with gold palladium, and imaged using a 
Hitachi ultra-high resolution FE-SEM S-4800. Fibrin fibre width was determined from the randomly 
selected images using the same methodology as has been described previously [20].   
 
Statistical Analysis 
 
This study aimed to investigate significant differences in df between subjects with sepsis, severe 
sepsis and septic shock. However, sample size calculation was based on our pilot data and involved 
detecting the smaller difference in subjects with sepsis, and severe sepsis of 0.07(±SD 0.06).  Hence 
using this minimum values to determine our sample size (expected difference of 0.07, power=0.9 
and SD ±0.06) and one-way ANOVA at three levels, a minimum sample of at least 15 subjects in each 
group was required for this study. The data are reported as mean and standard deviation or median 
and interquartile range where appropriate. Differences in frequency distribution used chi-squared 
analysis of nominal data across groups. Students T-test assessed differences between normally 
distributed groups, and Mann-Whitney U test was used for non-normally distributed groups. One-
way ANOVA with Bonferroni post-hoc correction was used to analyse for multiple group differences 
or alternatively a Kruskal-Wallis test for non-normally distributed data.  Data normality was assessed 
using the Shapiro-Wilk test with α value of 0.05. A binomial logistic regression using mortality as the 
binary response variable and PT and df as Continuous Predictor variables. The Goodness of Fit was 
determined by the Hosmer-Lemeshow and Pearson Methods and the Odds ratios together with their 
95% Confidence Intervals for the continuous variables calculated. All statistical analysis was carried 
out using SPSS for Windows, version 22.0 (Armonk, NY: IBM Corp.).  
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Results 
 
Baseline Characteristics of Patient Groups 
 
Baseline characteristics of the included patients are shown in table 1. 100 sepsis patients in total 
were included in the study. This included 50 patients with sepsis, 20 with severe sepsis and 30 with 
septic shock. 44 healthy volunteers matched for gender and age were also recruited as a healthy 
control group. Baseline characteristics reflected the severity of each group, with a significantly 
increased SOFA score, hospital length of stay, mortality and requirement for component 
replacement observed from sepsis through septic shock.  
 
Changes in Standard Markers of Coagulation across the Sepsis Spectrum 
 
Changes in coagulation markers across the different groups are shown in figure 1. Standard kinetic 
markers of coagulation PT and aPTT were significantly prolonged in septic shock (p < 0.001) when 
compared to other groups. PT was also significantly prolonged in severe sepsis compared to the 
healthy group (p < 0.005). An increased fibrinogen concentration was observed in sepsis and severe 
sepsis (p < 0.001) consistent with the underlying inflammatory response of the disease process. In 
the septic shock group, although fibrinogen concentration was significantly lower than in sepsis (p < 
0.01), it remained significantly higher than in the healthy group (p < 0.05). A significantly reduced 
platelet count was observed in patients with septic shock compared to all other groups (p<0.05) 
(Figure 1). Factor VIII activity was significantly lower in septic shock than both sepsis (p < 0.05), and 
severe sepsis (p = 0.001).Furthermore, D-Dimer was also significantly increased in septic shock 
compared to sepsis (p < 0.001), indicating increased fibrinolytic activity. 
 
Changes in Inflammatory Markers across the Sepsis Spectrum 
 
Inflammatory markers were measured on a subgroup of the total patients in order to quantify an 
increasing or decreasing inflammatory response with severity of group (40 sepsis, 13 severe sepsis, 
12 septic shock). Baseline measurements for inflammatory markers are shown in Table 2. A 
progressive increase in the inflammatory response from sepsis through to septic shock was 
observed. The inflammatory markers PCT and IL-8 were both significantly elevated in the septic 
shock group. 
  
Changes in Clot Microstructure (df) across the Sepsis Spectrum 
 
Changes in df in the sepsis groups compared to healthy volunteers are shown in Figure 1. A df of 1.74 
± 0.03 was observed in healthy volunteers, which is consistent with the healthy range that has been 
determined in previous studies [9–11]. df was significantly higher in subjects with sepsis and severe 
sepsis (1.78 ± 0.07 and 1.80 ± 0.05 respectively (p < 0.05)) and significantly lower df was observed in 
subjects with septic shock (1.66 ± 0.10 (p < 0.001)). This suggests clots formed in subjects with sepsis 
and severe sepsis are structurally dense, with increased fibrin branching and elasticity, whereas in 
septic shock clots formed are structurally weaker, with a tenuous fibrin structure with reduced 
branching and elasticity. 
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Computer Modelling of Mass Change at the Incipient Clot in Relation to df 
 
It is possible to quantify both the mechanical arrangement of the incipient clot and it’s mass through 
computer modelling techniques. Using these techniques previous studies have shown that a 
relatively small change in df equates to large changes in the fibrin mass incorporated into the clot 
[10, 19]. Therefore, to understand and define the change in fibrin mass and connectivity of the 
incipient clot, computer modelling was carried out (Figure 2). Using this model for incipient clot 
formation indicates the patients with the highest df form an incipient clot with 350% of the fibrin 
mass of the control group, whereas the patients with the lowest df form an incipient clot with 4% of 
the normal fibrin mass. 
 
Final Clot Imaging – Scanning Electron Microscopy 
 
Scanning electron microscopy was used to image the mature clot as a qualitative comparison for 
subjects across the sepsis spectrum. Clots formed from subjects with sepsis were denser and had 
thinner fibres than healthy individuals. Clots formed from subjects with septic shock appeared 
looser, with less fibrin thinner fibres than subjects with sepsis (Figure 3). 
 
Comparison between Survivors and non-Survivors at 28 Days 
 
All patients were followed up for all cause 28-day mortality. Characteristics of survivors and non-
survivors at 28 days are shown in Supplementary Table 1. A significant trend towards 
hypocoagulability was apparent in non-survivors compared to survivors.  Poor outcome was 
associated with a prolonged PT and reduced fibrinogen concentration. A weaker clot microstructure 
was also significantly associated with poor outcome, as indicated by significantly lower values of df in 
patients that did not survive 28 days. Furthermore, IL-8 and PCT were significantly associated with 
poor outcomes.  
 Binary Logistic Regression was undertaken on the two most significant coagulation variables 
(PT and df) as a predictor of mortality. PT and df were found to be significant predictors of mortality 
(p<0.0005) with odds ratios of 1.54 (CI 1.12 – 2.12) and 0.10 (CI 0.00 – 0.21) respectively. The odds 
ratio of less than 1 for df confirmed the significant effect of a lowered df on survival.  
 
 
Discussion 
 
This study demonstrates for the first time that a new functional biomarker of clot microstructure, df, 
can act as a significant biomarker for characterising changes in the mechanical properties of the clot 
in both the hyper and hypocoagulable phases of sepsis.  
Previous studies have shown how df is an accurate determinant for defining both the 
developing and the final clot architecture in acute vascular inflammatory conditions [11]. Increases 
in df have previously been shown to be characteristically associated with hypercoagulable states of 
vascular inflammatory disease and increasing clot strength [10, 11], whereas reduced values of df are 
associated with hypocoagulable states and a weakening of the mechanical clot properties [11, 20], 
[21]. 
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In the present study, we describe for the first time the changes that occur in clot 
microstructure across the clinically recognised stages of the sepsis spectrum. A significant increase in 
df was observed in patients with sepsis and severe sepsis, corresponding to formation of a tight, 
highly elastic incipient clot, that is potentially more resistant to fibrinolysis. In septic shock, there 
was a significantly lower df, corresponding to formation of a loose, structurally weak incipient clot, 
that is potentially more susceptible to fibrinolysis. 
As in previous studies the present study indicated a significant increase in the inflammatory 
response in septic shock [22]. Despite this increased inflammatory response, there was a profound 
reduction in df and mechanical strength of the developing clot in septic shock.  There are multiple 
factors that could contribute to this hypocoagulable effect. It has been shown that activity of clotting 
factors is reduced in septic shock, and this culminates in delayed and reduced thrombin generation 
[23]. This impairment of thrombin generation could lead to a lack of available fibrin to be 
incorporated into the incipient clot. Furthermore, in the present study patients with septic shock 
were significantly more acidotic and hypothermic, both of which have been shown to induce 
hypocoagulable effects and effect fibrin polymerisation and clot strength [24, 15]. 
In the hypercoagulable phases of sepsis and severe sepsis there was a significant increase in 
fibrinogen concentration, which is a known finding associated with the acute inflammatory response 
in sepsis [25]. In septic shock, fibrinogen concentration still remained significantly elevated when 
compared the healthy control, whereas there was a corresponding significant and marked reduction 
in df. This indicates that although there is an adequate concentration of fibrinogen in septic shock, 
the organisation of the fibrin clot microstructure formed was mechanically weak and porous 
compared to the matched healthy control group. This was confirmed in the scanning electron 
microscopy, where it was noted that there was an open clot, with visibly reduced incorporation of 
fibrin and branching which was also reflected by fibre width. 
The present study, utilising df scientifically determines and quantifies how mechanical clot 
strength in terms of its cross linking and connectivity changes as sepsis progresses. Donze et al. 
showed that with increasing severity of sepsis there is an increase in prothrombotic tendency and 
occurrence of thromboembolic events [26]. In this study df indicated a significant procoagulant 
change in clot microstructure in sepsis and severe sepsis, which could contribute to the recognised 
increased incidence of thromboembolic events [26]. Previous studies have shown how patients in 
septic shock undergo haemostatic changes due to consumption and coagulopathic effects, which 
could result in bleeding tendency [27, 28]. It is difficult to assess the relative risk of bleeding in septic 
shock, however, with previous studies reporting the incidence of major bleeding events at between 
1 and 20% [3, 29, 30], but no definitive study quantifying this bleeding risk. In this study, it was 
highlighted that despite sufficient platelet numbers and fibrinogen concentration in septic shock, 
there was still the inability to form a mechanically stable clot, as highlighted by df.   
Comparison of df against standard clinical markers of coagulation showed that in the 
hypercoagulable phase of sepsis, the standard markers were normal, despite an increased df. This 
confirms the lack of sensitivity of the standard markers of coagulation to hypercoagulable changes in 
sepsis. In septic shock there was as significant prolongation of aPTT and PT, which corresponded to a 
significant reduction in df.  
 It is well recognised that both thrombin generation and fibrinolytic function can be impaired 
in septic shock [27, 31]. Overall, these complex haemostatic changes can lead to a dichotomy, where 
a patient may have thromboembolic risk, but still be at risk of a bleeding diathesis, both of which 
may be clinically difficult to evaluate in the intensive care setting. Although in this study we did not 
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look at clinical outcomes or underlying mechanisms, df clearly quantified how the changes and the 
balance between the pro and anti-coagulant effects of coagulation could be assessed in terms of clot 
characteristics and strength. 
In order to investigate the structural characteristics of the mature clot across the sepsis 
spectrum and its relationship to df, we used SEM imaging. It has been shown previously that in 
hypercoagulable states, there is increased fibrin binding with an associated increase in fibrin mass 
and density of branching [32]. In this study it was confirmed that there was an alteration in clot 
microstructure in the different stages of sepsis, which has not been shown before. In the early 
hypercoagulable stages, SEM images showed increased branching, reduced poor space and thinner 
fibrin fibres. Conversely in septic shock, it was noted that although thinner fibrin fibres were 
observed, similar to in hypercoagulable states, the cross linking was reduced and pore spaces 
appeared larger, indicating a loosening of the clot architecture and implying a looser, weaker final 
clot structure due to less fibrinogen being incorporated into the polymerised clot mass. 
Altered clot structure and its mechanical properties were further investigated using 
computer modelling, where it was indicated that higher value of df were associated with a much 
greater polymerised fibrin mass of high connectivity consistent with a prothrombotic or 
hypercoagulable state. For the highest values of df that were observed, computer modelling 
indicated a corresponding 350% increase in fibrin mass incorporated into the clot, whereas for the 
lowest values of df the incipient clot had a fibrin mass of  less than 10% of that incorporated into a 
healthy clot. 
In previous studies it has been shown that df can characterise the mechanisms of clot 
microstructure in inflammatory diseased states at their various stages [10]. This study again confirms 
and fives further evidence that characterisation of clot architecture across the sepsis spectrum may 
give further understanding of the effects of sepsis and its inflammatory response on the coagulation 
system. However, further mechanistic studies are required to explore and determine the factors that 
underpin these changes in clot microstructure in patients who move from severe sepsis to septic 
shock. Further studies are underway to explore these mechanistic possibilities and also to 
investigate how these changes affect clinical outcome. 
 
 
Limitations 
 
This study has a number of limitations. Firstly this was a single centre observational study, and 
although some outcome data were presented, they were not powered for clinical outcome, as this 
was a proof of concept study. Furthermore, it was outside the scope of this study to seek 
mechanistic conclusions. The inherent problem of this study and other similar studies is the 
heterogeneity of the disease, its treatment and comorbidities. It is also difficult to take in to account 
the possible differences in concomitant medications and treatment between the groups. To assess 
these effects fully a much larger study would be required. Further larger prospective studies are 
required to build on the findings of this study. 
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Tables 
 
Table 1: Baseline characteristics of healthy volunteers and sepsis patients: Demographic 
information and baseline characteristics are shown for each of the sepsis groups and the healthy 
control group. Significance values assessed by One-way ANOVA, Kruskal-Wallis test and Pearson Chi-
Square test where appropriate. SOFA, sepsis-related organ failure assessment. 
 
 Healthy Sepsis Severe Sepsis Septic Shock Significance 
Value 
N 44 50 20 30  
Age (years) 60.8 ± 18.6 59.6 ± 19.8 66.3 ± 17.4 66.6 ± 14.9 0.268 
Male Gender (n 
[%]) 
22 [50] 24 [48] 9 [45] 18 [60] 0.693 
Source of 
Infection 
    0.398 
Respiratory - 29 [58] 12 [60] 11 [37]  
Urinary Tract - 8 [16] 4 [20] 7 [23]  
Abdominal - 9 [18] 1 [5] 9 [30]  
Soft Tissue - 2 [4] 1 [5] 0 [0]  
Other/Unknown - 2 [4] 2 [10] 3 [10]  
SOFA Score - 3 (1, 3.5) 5 (4, 6) 9.5 (6.75, 12) <0.001 
Hospital Length 
of Stay (days) 
- 6.0 (2, 9) 9.0 (5, 18) 15.0 (3.75, 
37.5)  
0.006 
28 Day Mortality 
(n [%]) 
- 1 [2] 3 [15] 13 [43] <0.001 
Required 
Component 
Replacement 
During Stay (n 
[%]) 
- 0 1 [5] 6 [20] 0.003 
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Table 2: Inflammatory markers in sepsis patients: Concentrations of the different inflammatory 
markers are shown for the different sepsis groups. Data is presented as median (IQR). Significance 
values assessed using Kruskal-Wallis test. *Significantly different from sepsis group (p = 0.001), 
**Significantly different from both sepsis (p < 0.001) and severe sepsis (p < 0.05) (Kruskal-Wallis test, 
post-hoc pairwise comparisons, Bonferroni correction). 
 
 Sepsis Severe Sepsis Septic Shock Significance 
Value 
CRP (mg/dL) 79 (39.5, 221.5) 193 (124, 422) 127.5 (21.0, 
127.5) 
0.078 
PCT (pg/mL) 307.6 (108.3, 
1037.5) 
702.4 (384.5, 
1637.1) 
1257.6 (230.3, 
17295.7)* 
0.001 
TNF-α (pg/mL) 4.0 (2.9, 30.5) 6.2 (4.8, 34.5) 40.6 (10.4, 249.3) 0.110 
IL-6 (pg/mL) 320.7 (67.6, 
651.7) 
202.8 (137.5, 
532.6) 
743.9 (103.5, 
822.3) 
0.062 
IL-8 (pg/mL) 61.4 (20.6, 176.2) 71.1 (40.9, 103.7) 525.7 (136.1, 
7997.9)** 
<0.001 
e-Selectin 
(ng/mL) 
70 (37, 127) 54 (20.5, 118.5) 37 (33.8, 74.8) 0.584 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Figure 1: Changes in markers of coagulation across the sepsis spectrum: Markers of coagulation 
across the sepsis spectrum and compared to the healthy control group are shown. Normally 
distributed data are presented as means plots with the error bars representing the standard 
deviation of the data. Non-normally distributed data are presented as box plots (median and IQR) 
with whiskers representing the range. Significant differences are shown (Bonferroni corrected post-
hoc analysis; Multiple comparisons made using one-way ANOVA for normalised data and Kruskal-
Wallis for non-normalised data)).  
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Figure 2: Computational analysis of fibrin mass curve: A) Graph illustrating the non-linear 
relationship between fibrin mass incorporated into the incipient clot and df. The mass on the y-axis is 
normalised for the control of df = 1.74. The following values of df were put into the model: df = 1.74 
(healthy), df = 1.45 (septic shock) and df = 1.85 (sepsis/severe sepsis). The respective mass of each df 
is indicated by O, X and □ respectively. Accompanying diagrams of fractal structures indicate the 
fibrin mass incorporated into fractal structures of df = 1.74, 1.45 and 1.85. The colour of each node 
represents the local density of nodes within a sphere of radii 5 units, colour ranging from green (1 
node) to red (20 nodes). In basic terms the red nodes represent an increased degree of connectivity 
in terms of elastic clot strength.  
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Figure 3: SEM images and corresponding fibrin fibre widths for different sepsis groups: 
Representative images of mature whole blood clots are shown for a healthy individual (df = 1.73), 
sepsis patient (df = 1.83) and septic shock patient (df = 1.61). A means plot illustrating the changes in 
fibre width across the different groups is also shown (n = 3). A progressive decrease in fibre width 
was observed with increasing severity of sepsis. In septic shock, low df appeared to correspond with 
less fibrinogen incorporated into the polymerised clot mass, despite there being a sufficient 
fibrinogen concentration. The micrograph scale bar applies to all images and is 10µm long.  
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Supplementary Table 1: Relationship between coagulation parameters and outcome: Comparison 
of the different coagulation parameters between survivors and non-survivors at baseline. Data 
presented as mean ± SD or median (IQR). Significance values assessed using Students t-test for 
normally distributed data, and Mann-Whitney U test for non-normally distributed data. 
 
 Survivors (n=83) Non-survivors (n=17) Significance Value 
aPTT (sec) 27.25 (25.5, 30.6) 30.3 (25.5, 42.4) 0.087 
PT (sec) 11.2 (10.5, 12.0)  12.9 (11.6, 15.6) 0.001 
Fibrinogen (g/L) 4.75 (4.025, 4.75) 3.5 (2.3, 4.775) 0.012 
Platelets (x109/L) 249 ± 108 227 ± 138 0.465 
df 1.76 ± 0.08 1.66 ± 0.12 <0.001 
 
 
 
